Novartis radioligand therapy Lutathera FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors Read more
Incyte Announces Acquisition Of Escient Pharmaceuticals And Its Pipeline Of First-In-Class Oral MRGPR Antagonists Read more
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Read more
Ochre Bio announces partnership with Boehringer Ingelheim to develop novel regenerative treatments for patients with advanced liver disease Read more
European Commission Approves Pfizer’s EMBLAVEO for Patients with Multidrug-Resistant Infections and Limited Treatment Options Read more
ImmunityBio Announces FDA Approval of ANKTIVA, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Read more
TriLink BioTechnologies Announces New San Diego Facility for Late Phase mRNA Drug Substance Production Read more
Evotec and Variant Bio enter strategic partnership to discover and develop fibrosis treatments Read more